ASH: AlloHSCT Feasible After PD-1, PD-L1 mAb in Hodgkin Lymphoma

TUESDAY, Dec. 10, 2019 -- Allogeneic hematopoietic stem cell transplantation (alloHSCT) performed after programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAB) treatment seems feasible for patients with...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news